Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
adverse events
metastatic castration-resistant prostate cancer
multidisciplinary management
prostate-specific membrane antigen
radiopharmaceutical therapy
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
03 Oct 2024
03 Oct 2024
Historique:
received:
05
07
2024
accepted:
09
09
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent
Identifiants
pubmed: 39362764
pii: jnumed.124.268363
doi: 10.2967/jnumed.124.268363
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 by the Society of Nuclear Medicine and Molecular Imaging.